Akums Drugs and Pharmaceuticals Ltd (AKUMS) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Akums Drugs and Pharmaceuticals is a pharmaceutical formulations manufacturer spanning CDMO, domestic and international branded formulations, trade generics and APIs, with CDMO contributing 82.6% of Q1 FY27 revenue. The Q2 print will speak to whether the 15.0% EBITDA margin of Q1 holds within management's guided 14-15% FY27 band amid API price volatility, and whether the $25 million Zambia supply commitment from Indian plants commenced by end-Q2 FY27.

Akums Drugs and Pharmaceuticals Ltd Q2 Results Date and Time

The board of Akums Drugs and Pharmaceuticals Ltd is scheduled to meet on Monday, November 2, 2026, to approve the un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, under Regulation 29 of SEBI LODR. The closed trading window reopens 48 hours after results declaration.

A virtual analysts call is scheduled for November 3, 2026, at 12:00 PM IST. Speakers include Managing Directors Sanjeev Jain and Sandeep Jain, CFO Sumeet Sood, and Head Strategy Sahil Maheshwari; no UPSI will be shared.

What to expect from Akums Drugs and Pharmaceuticals Ltd's Q2 FY27 results

The quarter tests whether Akums' volume-led, market-outperforming growth held through Q2 FY27, after Q1 FY27 delivered high-teens volume growth against IPM MAT unit growth of roughly 1.5% at MAT September 2026. The IPM backdrop was supportive, with monthly value growth of 12.1% in July, 10.7% in August and 13.5% in September, and volumes rebounding to a two-year high of 3.4-3.5% in September after an August trough of 1.1%. Management has guided FY27 EBITDA margin at 14-15% with an inclination toward the upper bracket after Q1 printed 15.0%, and the API segment turned EBITDA positive in Q1 per the MD message, ahead of the stated end-Feb/Mar 2027 monthly-positivity timeline. Power and fuel costs are a stated pressure point, with WPI fuel and power inflation at 25.85% in September 2026 and spot day-ahead electricity prices averaging Rs. 7.3/unit, more than double year-earlier, while the rupee's move from around 94.80 to a provisional close of 95.81 on September 30 is a conversion tailwind for the export CDMO book. The NPPA demand of Rs. 52.75 Cr on subsidiary Pure and Cure, received October 15, 2026, is a post-quarter item where the company states prime responsibility to respond lies with marketer Hetero Healthcare. The upcoming call is expected to cover the margin bridge against the 14-15% band, Zambia supply commencement, API segment run-rate, and H1 capex against the Rs. 300 Cr FY27 target.

Key Things To Watch

Performance vs Guidance Tracking: Status of management's stated targets heading into the Q2 FY27 print.

• EBITDA margin — 14-15%, upper bracket for FY27 — Q1 printed 15.0%; check whether Q2 holds the upper bracket amid API volatility
• API monthly EBITDA positivity — by end Feb/Mar FY27 — Q1 MD message claims API EBITDA positive; confirm monthly run-rate and FY28 profit contribution
• Zambia supplies — $25M from Indian plants by end Q2 FY27 — start was questioned in the Q1 call; confirm whether Q2 supplies began and INR 240-odd Cr H2 tracking
• Capex — INR 300 crores for FY27 — H1 FY27 spend vs target; Q1 response was 'still discussing'
• CDMO base margins — from 13-14% toward 15-16% by FY28 — Q4 FY26 at 14.4%; trajectory with Zambia/Europe ramp

Europe Plant 2 and marketing segments

• Europe Plant 2 (oral liquids, Haridwar) supplies planned for FY28 — dossier/registration progress and cessation of the INR 19 Cr/quarter notional interest once supplies begin
• Marketing segments — above-IPM growth guided for FY27 — recovery after muted Q1; field-force expansion of 200 people
• Trade generics positive since Q4 FY26 and API losses curtailed — sustain TG breakeven and confirm API EBITDA sign

NPPA demand and Oriflame integration

• NPPA demand of Rs. 52.75 Cr on subsidiary Pure and Cure (Oct 2026) — any provisioning, exceptional item, or liability commentary vs the Hetero Healthcare contractual position
• Oriflame India acquisition — Rs 56 Cr deal announced July 23 — integration progress and skincare/cosmetics margin impact
• Q2 FY27 volumes — 'high teens' indicated — whether double-digit volume momentum continued

Operating metric trajectory

• Capacity utilization at ~50% in Q1 FY27 vs 44% for FY26, with peak operational capacity of 55% for oral solids — watch for any narrative shift on utilization strategy
• API prices turned upward in Q1 FY27 after three quarters of decline, but management flagged that volatility remains high in Q2 FY27
• Corporate gross margin rose 1.5% in Q1 FY27, mostly from high-value products being added; management expects sustainability 'plus or minus 0.5%'